Immix Biopharma Inc (IMMX) - Total Assets
Based on the latest financial reports, Immix Biopharma Inc (IMMX) holds total assets worth $20.08 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Immix Biopharma Inc (IMMX) net assets for net asset value and shareholders' equity analysis.
Immix Biopharma Inc - Total Assets Trend (2019–2024)
This chart illustrates how Immix Biopharma Inc's total assets have evolved over time, based on quarterly financial data.
Immix Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Immix Biopharma Inc's total assets of $20.08 Million consist of 88.0% current assets and 12.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.1% |
| Accounts Receivable | $1.97 Million | 8.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Immix Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Immix Biopharma Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immix Biopharma Inc's current assets represent 88.0% of total assets in 2024, a decrease from 99.0% in 2019.
- Cash Position: Cash and equivalents constituted 77.1% of total assets in 2024, down from 77.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Immix Biopharma Inc Competitors by Total Assets
Key competitors of Immix Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Immix Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 3.47 | 0.10 |
| Quick Ratio | 1.53 | 3.47 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.73 Million | $16.19 Million | $-4.74 Million |
Immix Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Immix Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 46.96 |
| Latest Market Cap to Assets Ratio | 16.91 |
| Asset Growth Rate (YoY) | 15.2% |
| Total Assets | $22.95 Million |
| Market Capitalization | $388.16 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Immix Biopharma Inc's assets at a significant premium (16.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Immix Biopharma Inc's assets grew by 15.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immix Biopharma Inc (2019–2024)
The table below shows the annual total assets of Immix Biopharma Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $22.95 Million | +15.17% |
| 2023-12-31 | $19.93 Million | +33.65% |
| 2022-12-31 | $14.91 Million | -18.05% |
| 2021-12-31 | $18.19 Million | +3271.42% |
| 2020-12-31 | $539.60K | -42.78% |
| 2019-12-31 | $942.94K | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1… Read more